Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

KPV: mechanism of action

KPV is the endogenous tripeptide Lysine-Proline-Valine, a fragment of alpha-melanocyte-stimulating hormone. This page sets out what laboratory work reports about its mechanism, and where that evidence is in vitro or anim

peptides-pro Editorial

KPV is the tripeptide Lysine-Proline-Valine, also written Lys-Pro-Val, an endogenous fragment derived from alpha-melanocyte-stimulating hormone (alpha-MSH) [2][3]. It is a short-chain peptide of three residues, and the evidence block for this page does not supply a full sequence string, molecular formula or molecular weight, so none is stated here. In the research literature it is handled as an anti-inflammatory and antioxidant peptide, and it appears alongside other short anti-inflammatory peptides such as Ac-QAW and IRW in delivery-engineering work [1].

The mechanistic work centres on redox-sensitive signalling: reactive oxygen species (ROS) as the upstream trigger, and the AKT/mTORC1/PPARgamma axis as the downstream pathway examined in lipid-handling models [2][3].

Research Studies

KPV and gastrointestinal stability in oral delivery models

Oral delivery of peptide therapeutics is limited by degradation in the gastrointestinal tract and poor intestinal absorption [1]. A self-immolative peptide prodrug conjugate (SIPPC) platform was designed to address both problems, combining a hydrophilic polyethylene glycol segment, a ROS-responsive hydrophobic self-immolative module, and a hydrolyzable scaffold; these components assemble spontaneously into micelle-like nanoparticles [1].

KPV was one of three anti-inflammatory peptides tested in that platform, alongside Ac-QAW and IRW. The engineered conjugates were reported to show gastrointestinal stability, mucus penetration, and ROS-responsive release at inflamed tissue [1]. This is formulation and delivery work rather than a statement about KPV's intrinsic pharmacology, and the findings are reported for the conjugate system, not for free peptide administered to humans.

KPV and adipogenesis in differentiating adipocytes

KPV has been described as an endogenous tripeptide with anti-inflammatory and antioxidant activity, but its role in adipocyte differentiation was not previously investigated [2]. In that study the regulatory effects of KPV on MDI-induced differentiation were examined, and the reported mechanism was modulation of ROS-mediated AKT/mTORC1/PPARgamma signalling [2].

The readout is adipogenesis and lipid metabolism in a cell-differentiation model. The evidence block does not give the cell line, the concentrations tested, or effect sizes, so those are not reported here. This is in vitro work.

KPV and hepatic lipid accumulation in HepG2 cells

Hepatocellular steatosis is an early stage within the non-alcoholic fatty liver disease spectrum and is characterised by excessive lipid accumulation and oxidative stress in hepatocytes [3]. A study examined the protective role of KPV in that context, reporting attenuation of hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway in HepG2 cells [3].

As with the adipocyte work, the mechanism is framed as redox-dependent and converging on PPARgamma. The model is a hepatocyte cell line, so the finding is in vitro and does not by itself establish what happens in intact liver tissue.

KPV and the shared ROS/PPARgamma axis across lipid-handling models

Two independent in vitro reports place KPV's lipid effects on the same upstream node. In differentiating adipocytes the pathway is given as ROS-mediated AKT/mTORC1/PPARgamma [2]; in HepG2 hepatocytes it is given as ROS-dependent regulation of PPARgamma [3]. The convergence is on ROS as the trigger and PPARgamma as the downstream transcription factor, with AKT/mTORC1 appearing in the adipocyte arm.

ModelCell type / systemReported pathwayReported outcome
Adipocyte differentiationDifferentiating adipocytes (MDI-induced)ROS-mediated AKT/mTORC1/PPARgammaAttenuation of adipogenesis and altered lipid metabolism [2]
Hepatocellular steatosisHepG2 cellsROS-dependent PPARgamma regulationAttenuation of hepatic lipid accumulation [3]

Both rows are in vitro. Neither report is a clinical study, and the table compares two cell models rather than two species or two dose levels.

KPV and ROS-responsive release at inflamed tissue

The SIPPC design exploits the same redox chemistry that the cell studies implicate in KPV's downstream signalling. The conjugate carries a ROS-responsive hydrophobic self-immolative module, so release is triggered by reactive oxygen species at the target site rather than by bulk hydrolysis [1]. In the reported work this produced ROS-responsive release at inflamed tissue together with mucus penetration and gastrointestinal stability [1].

This is a materials-chemistry mechanism: the ROS sensitivity belongs to the conjugate, not to KPV itself. It is worth separating the two when reading the delivery literature.

KPV and host defense peptide strategies in inflammatory bowel disease

Inflammatory bowel diseases are chronic disorders of the gastrointestinal tract causing severe inflammation and tissue damage, and existing treatments carry adverse effects, which has driven interest in alternatives [5]. A short review of host defense peptides positions this peptide class as a promising lead for inflammatory bowel disease strategies [5].

KPV is discussed within that broader peptide class rather than as the subject of a dedicated trial in the review. The evidence block does not report a specific KPV endpoint from this source, so no such endpoint is claimed here.

KPV and the peptide-class context in sport and bodybuilding

A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides and peptide analogues, which are marketed as more selective and ostensibly safer alternatives [4]. Growth hormone secretagogues such as Ipamorelin are named among the agents discussed [4].

This source is included for class context only. The evidence block does not report KPV-specific findings from it, and no KPV claim is drawn from it here.

KPV and what the current evidence does not establish

Across the sources available for this page, the mechanistic claims for KPV rest on cell-culture models of adipocyte differentiation and hepatocellular steatosis [2][3], on a nanoparticle delivery platform tested with three peptides including KPV [1], and on review-level discussion of peptide classes [4][5]. There is no human pharmacokinetic or clinical outcome data in this evidence block.

  • No sequence string, molecular formula or molecular weight is supplied by the evidence block, so none is given.
  • No receptor has been named as KPV's direct binding target in the evidence block; the pathway is described in terms of ROS, AKT/mTORC1 and PPARgamma [2][3].
  • No dose, exposure or effect size is reported in the evidence block for any model.
  • The delivery findings belong to the conjugate system, not to unmodified peptide [1].

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing, administration or medical guidance of any kind. Nothing on this page is a recommendation to use KPV or any other compound in a person. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp